Maryland is currently home to 2684 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acute Kidney Injury
Register for Updates
NXT Post-Market Clinical Follow-up
NCT06336304
Recruiting
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: Chesapeake Urology Hanover, Hanover, Maryland
Conditions: Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Incontinence, Urge
Register for Updates
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
NCT05488340
Recruiting
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an activ... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Research Site 128, Owings Mills, Maryland
Conditions: Urinary Tract Infections
Register for Updates
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT02674100
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough
NCT06504446
Recruiting
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/21/2025
Locations: Continental Clinical Solutions, LLC, Towson, Maryland
Conditions: Refractory or Unexplained Chronic Cough
Register for Updates
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
NCT06153420
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: DelRicht Research of Bethesda Clinical Trials, Rockville, Maryland
Conditions: Irritable Bowel Syndrome With Diarrhea
Register for Updates
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06059118
Recruiting
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Prostate Cancer
Register for Updates
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
NCT05083754
Recruiting
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/21/2025
Locations: Johns Hopkins Medical Institution, Baltimore, Maryland
Conditions: Glioblastoma Multiforme
Register for Updates
A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia
NCT06681766
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/20/2025
Locations: Uncommon Cures, Chevy Chase, Maryland
Conditions: Friedreich Ataxia
Register for Updates
Efficacy and Safety Study of OATD-01 in Patients with Active Pulmonary Sarcoidosis
NCT06205121
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Molecure Investigative Site, Baltimore, Maryland
Conditions: Pulmonary Sarcoidosis
Register for Updates
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
NCT06027086
Recruiting
The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/20/2025
Locations: Johns Hopkins SKCCC, Baltimore, Maryland
Conditions: Fibrolamellar Hepatocellular Carcinoma
Register for Updates
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
NCT05155033
Recruiting
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma. Researchers want to see if these drugs can be used together to produce better results in people with these types of cancer. Objective: To learn if the combination of pembrolizumab and aldesleukin can be used to treat metastatic or advanced melanoma and renal cell cancer. Eligibility: Adults aged 18 years or older who have metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
Register for Updates